Ingevity Corporation completed its acquisition of the Capa™ caprolactone division of Perstorp Holding AB, including its monomer facility in Lower Walton, Warrington, on Feb. 13. Following the close, Ingevity President and CEO Michael Wilson and members of his leadership team visited the facility. In meetings with employees and community leaders on Feb. 18, Wilson expressed his commitment to the plant, its employees and to the community.
“We are very pleased to be adding such a unique business to our company,” said Michael Wilson. “By combining our businesses, we are creating an even stronger, market-leading business focused on high-growth end-use applications. We intend to invest aggressively here in Warrington to bring a broader, richer set of solutions and products across industries to our customers. Moreover, we’re excited to welcome our new employees in Warrington and across the globe.”
Cllr Russ Bowden, Leader of Warrington Borough Council, said, “We’re delighted that Ingevity has made this considerable investment in Warrington, with plans for ongoing investment in this internationally significant caprolactone plant. In addition, Ingevity prides itself on community support and volunteering, and we’re looking forward to developing a strong relationship with the company.”
Capa is the global market leader in the production and commercialization of caprolactone and high-value downstream derivatives. The division’s products are key components in adhesives, bioplastics, coatings, elastomers and resins. Ingevity provides specialty chemicals and high-performance carbon materials and technologies that purify, protect and enhance the world around us. Ingevity will include the caprolactone business in the company’s Performance Chemicals segment and report revenues as “Engineered Polymers.”
Headquartered in North Charleston, South Carolina, Ingevity operates from 25 locations around the world and employs approximately 1,700 people. For more information visit www.ingevity.com.